Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema.
Grouzmann
Eric
E
Livio
Françoise
F
Buclin
Thierry
T
D000218:Adamantane / Q000009:adverse effects / Q000031:analogs & derivatives; D000799:Angioedema / Q000139:chemically induced*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects*; D004357:Drug Synergism; D006801:Humans; D008954:Models, Biological; D009570:Nitriles / Q000009:adverse effects; D011759:Pyrrolidines / Q000009:adverse effects; D012307:Risk Factors; D000077597:Vildagliptin
D000806:Angiotensin-Converting Enzyme Inhibitors; D054873:Dipeptidyl-Peptidase IV Inhibitors; D009570:Nitriles; D011759:Pyrrolidines; D018819:Dipeptidyl Peptidase 4; D000077597:Vildagliptin; D000218:Adamantane